Clinical trials: Pulmonary Disease (COPD), Chronic Obstructive
- Condition Pulmonary Disease (COPD), Chronic Obstructive
- Funder type Industry (pharma, biotech, devices)
COPD
Impact of Ibis on Patients With Advanced COPD
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients with COPD.
- Trial name
- NCT03131622
- Testing
- Digital Therapeutics
- Volunteers
- 240 people
- Sponsor
- Senscio Systems
Chronic Obstructive Pulmonary Disease (COPD)
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the efficacy and safety of QVA149 compared to tiotropium plus formoterol in patients with moderate to severe COPD.
- Trial name
- QUANTIFY (NCT01574651)
- Testing
- QVA149, Tiotropium, Formoterol
- Where
- 144 sites in Germany
- Volunteers
- 934 people
- Sponsor
- Novartis Pharmaceuticals
COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, Safety and Efficacy Study of Taneasy 600mg Granules and Fluimucil 600mg Granules in COPD Subjects
To evaluate the safety and efficacy of Taneasy 600mg granules and Fluimucil 600mg granules administered twice daily for 14 days in treatment of COPD Disease.
- Trial name
- NCT06828120
- Testing
- Taneasy 600mg granules, Fluimucil 600mg granules
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Bun Yao Biotechnology Co., Ltd
Pulmonary Disease, Chronic Obstructive
Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease
To collect post-marketing safety and effectiveness information on the use of Tiotropium Inhalation Capsules (18 μg) in patients with chronic obstructive pulmonary disease in daily clinical settings
- Trial name
- COPD (NCT02177318)
- Testing
- Spiriva (tiotropium bromide) inhalation capsules
- Where
- 418 sites in Japan
- Volunteers
- 3,588 people
- Sponsor
- Boehringer Ingelheim
COPD
A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD
The purpose of this study is to evaluate the safety and efficacy of the concomitant treatment of formoterol fumarate with tiotropium bromide compared to treatment with tiotropium bromide alone.
- Trial name
- NCT00308191
- Testing
- Formoterol Fumarate, Tiotropium Bromide
- Where
- 17 sites in United States
- Volunteers
- 128 people
- Sponsor
- Dey
Pulmonary Disease, Chronic Obstructive
Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD
Comparison of 18 mcg of Tiotropium Inhalation Capsules and ipratropiumMetered Dose Inhaler (2 puffs of 20 mcg, four times daily) in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults with Chronic Obstructive…
- Trial name
- NCT00274040
- Testing
- Tiotropium, Ipratropium
- Where
- 18 sites in South Korea
- Volunteers
- 141 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow.
- Trial name
- NCT05638776
- Testing
- REGEND001 cell therapy
- Where
- 8 sites in China
- Volunteers
- 58 people
- Sponsor
- Regend Therapeutics
Pulmonary Disease, Chronic Obstructive, COPD
Study to Assess the Effect of the Aerobika Device in Addition to Standard of Care Treatment in Sputum Producing COPD Patients Using FRI
Primary: The primary objective of this study is to evaluate the effect of the Aerobika® device on the aerosol deposition pattern of concomitant inhalation medication using FRI.
- Trial name
- NCT02936817
- Testing
- Aerobika® Device, HRCT scans
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- FLUIDDA nv
Pulmonary Disease, Chronic Obstructive
SPIRIVA in Ususal Care
The objective of the study is to determine the effect on lung function when either SPIRIVA once daily or placebo once daily is added to the usual therapy (care) of COPD patients naïve to anticholinergic agents managed in primary…
- Trial name
- NCT00274079
- Testing
- SPIRIVA
- Where
- 44 sites in United Kingdom
- Volunteers
- 395 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer, Small Cell Lung Cancer
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma
- Trial name
- NCT05337163
- Testing
- Diagnostic Test: Sputum DNA methylation analysis, chest CT or pathological examination
- Where
- China
- Volunteers
- 1,564 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Healthy
DBM-1152A Inhalation Solution in Healthy Volunteers
This is a single-center, randomized, double-blind, placebo-controlled Phase 1b study to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple-dose DBM-1152A inhalation solution in healthy Chinese adults.
- Trial name
- NCT07439419
- Testing
- DBM-1152A
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
This is a placebo-controlled, double-blind, parallel, randomized, two-part, dose-confirming clinical study characterizing the pharmacodynamic effects of pulsed iNO using the combination product, inhaled nitric oxide/INOpulse DS-C…
- Trial name
- NCT01728220
- Testing
- Inhaled NO delivered via INOpulse DS-C Device
- Where
- 43 sites in United States
- Volunteers
- 159 people
- Sponsor
- Bellerophon Pulse Technologies
Moderate to Severe COPD
Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to study efficacy and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- Columbus (NCT00690482)
- Testing
- AZD1981
- Where
- 21 sites in Bulgaria, Denmark and 3 more
- Volunteers
- 118 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging
In this study the efficacy of Roflumilast in addition to LAMA/LABA therapy will be assessed using Functional Respiratory Imaging.
- Trial name
- NCT02451540
- Testing
- HRCT scan, Roflumilast
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- FLUIDDA nv
Pulmonary Disease, Chronic Obstructive
Evaluation of COPD Co-Pilot
The purpose of this research study is to investigate the potential benefits of participant use of a smartphone application ("App") called COPD Co-Pilot™.
- Trial name
- NCT02944591
- Testing
- COPD Co-Pilot
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- HGE Health Care Solutions, LLC
Chronic Obstructive Pulmonary Disease (COPD)
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01727141
- Testing
- QVA149, QAB149, NVA237
- Where
- 143 sites in United States, Canada and 6 more
- Volunteers
- 1,042 people
- Sponsor
- Novartis Pharmaceuticals
COPD
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
- Trial name
- NCT00215436
- Testing
- Formoterol Fumarate
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Dey
Pulmonary Disease, Chronic Obstructive
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease
The objective of this study was to compare the bronchodilator efficacy and safety of ipratropium bromide HFA-134a inhalation aerosol and marketed, Atrovent® CFC Inhalation Aerosol in COPD patients
- Trial name
- NCT02260011
- Testing
- Ipratropium bromide HFA-134a inhalation aerosol, Atrovent® CFC inhalation aerosol
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Study to Investigate Daily Symptom Variability, Symptom Effects on Morning Activities of Chronic Obstructive Disease
The primary objective of this non-interventional study is to evaluate daily symptom variability in COPD patients. The secondary objectives are; to evaluate effects of COPD symptoms on the morning activities of patients, to…
- Trial name
- NCT01110564
- Where
- 19 sites in Turkey (Türkiye)
- Volunteers
- 515 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)
Comparison of lung function response between tiotropium inhalation solution and Spiriva HandiHaler.
- Trial name
- NCT00281567
- Testing
- Tiotropium, Respimat SMI, HandiHaler
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 76 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.